Sector News

Teva Pharm to close plant in Israel after no buyer found

April 10, 2018
Life sciences

Debt-laden Teva Pharmaceutical Industries said on Monday it would close an unprofitable plant in the Israeli port city of Ashdod in March 2019 after failing to find a buyer for the facility.

Teva, the world’s largest generic drugmaker and Israel’s biggest company, said in a statement half of the factory’s 175 workers would lose their jobs in the coming months with the rest continuing to work until the plant closes.

In December, Teva said it would cut 14,000 jobs – 25 percent of its global workforce – and close many plants as part of a restructuring aimed at helping to pay down debts.

“The Teva Ashdod plant is part of the reorganization process being carried out in Israel and around the world in order to reduce the cost base due to the heavy debt the company faces and the complex business circumstances it is dealing with,” Teva said in an emailed statement to Reuters.

“Teva has examined the possibility of selling the plant in recent months but unfortunately no suitable buyer was found,” it said.

Teva said some of the plant’s activities were outside of its core areas and the production of IV bags – which accounts for half the plant’s activity – was not profitable.

The company had been saddled with nearly $35 billion of debt after it bought Allergan’s Actavis generic drug business for $40.5 billion in 2016.

In February, it said it had reduced its debt by $1.1 billion from the end of 2017 while also selling bonds to restructure its short-term debt.

Israel’s Histadrut labor federation criticized Teva’s decision to shut the Ashdod plant, saying the company had no intention of strengthening or maintaining its activity in Israel.

Teva said it was holding a dialogue with labor unions to complete the layoffs with agreements.

By Steven Scheer

Source: Reuters

comments closed

Related News

January 15, 2022

Colorcon Ventures invests in AI-Driven bio-simulation company VeriSIM Life

Life sciences

Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.

January 15, 2022

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.

January 15, 2022

Sanofi cuts ties with Sangamo, sharpening focus on ‘off-the-shelf’ cell therapy

Life sciences

Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.

Send this to a friend